2023-02-22

Press Release: BD Onclarity™ HPV Assay Receives FDA Approval for Use with Both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test

BD Onclarity HPV Assay

The BD Onclarity™ HPV Assay has received FDA Approval for use with both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test, which expands access to the HPV test that more precisely identifies patients’ risk for cervical cancer.

“When more people with a cervix are better able to manage their health through more accurate and precise testing, we are taking another step forward toward eliminating cervical cancer in our lifetimes,” said Dr. Jeff Andrews, Vice President of Medical Affairs for BD.

ThinPrep is a trademark of Hologic, Inc.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

ReachMD: A review of risk in cervical cancer: An analysis of the ASCCP guidelines & NCI risk matrix
Cervical Cancer | Webinars & Videos
ReachMD: A review of risk in cervical cancer: An analysis of the ASCCP guidelines & NCI risk matrix
BD Onclarity™ HPV Assay with extended genotyping
Cervical Cancer | Brochures
BD Onclarity™ HPV Assay with extended genotyping
Contemporary OB/GYN: BD Onclarity™ HPV Assay: What it means for the future of cervical cancer detection
Cervical Cancer | News & Updates
Contemporary OB/GYN: BD Onclarity™ HPV Assay: What it means for the future of cervical cancer detection